Merck’s Verubecestat Safely Lowers Amyloid in Alzheimer’s, But Cognitive Benefits Not Yet Proven

Merck’s Verubecestat Safely Lowers Amyloid in Alzheimer’s, But Cognitive Benefits Not Yet Proven
Merck’s amyloid-lowering drug, verubecestat, has proceeded to Phase 3 clinical trials after early studies showed it safely lowered the levels of amyloid-beta, the protein linked to neurodegeneration in the brains of Alzheimer’s disease patients. Although the news may be reason for optimism, it remains to be seen if the treatment also can stymie or even improve

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. Andre says:

    So what happens if the remainder of the study goes well? If it does, how long before we begin to get access to this medication in the pharmacies? I believe my father may be developing Alzheimer’s and I want to know if there’s anything I can do to help stop it from developing further.

    • Magdalena Kegel says:

      Dear Andre,
      I am sorry to hear about your father.
      The first results of the ongoing trials are expected in July 2017, but it is difficult to say if, and when the drug will reach the market.

Leave a Comment

Your email address will not be published. Required fields are marked *